Role of insulin sensitising agents in altering PSA level in PCOS

Rajashree Panigrahy, Bratati Singh, Tapan K. Pattnaik, Sanjukta Misra


Background: Ovarian androgen production can be promoted by insulin resistance which leads to reproductive abnormalities in Polycystic Ovarian Syndrome (PCOS). A wide variety of female tissues can synthesize and secrete Prostate Specific Antigen (PSA). Androgens may take part a significant role in PSA secretion in PCOS. As insulin resistance stimulates androgen production, the baseline value of PSA may decline by insulin sensitising agents in PCOS. Present study is an attempt to measure the function of PSA as a marker of androgen excess in PCOS and to assess the role of insulin sensitising agent metformin in altering PSA level in PCOS.

Methods: The study was undertaken to assess the insulin resistance, testosterone and PSA level in 45 women diagnosed as PCOS and 45 healthy controls. Alteration of insulin resistance, serum testosterone and PSA levels by metformin was also analysed.

Results: A significant increase in testosterone, PSA level and insulin resistance was observed in PCOS cases when compared with control (p<0.001). When metformin was given for 4 months, improvement in insulin resistance and testosterone level was found in cases, but PSA values observed no change. Correlation was not found linking insulin resistance with PSA level prior to and after therapy.

Conclusions: Serum PSA level could be detected in high significant concentration in PCOS women. Various researches explain that insulin resistance and BMI may perhaps control serum PSA level, but our result demonstrate no effect of insulin sensitising agent on serum PSA value.


Polycystic ovarian syndrome, Insulin resistance, Metformin, Prostate specific antigen

Full Text:



Norman RJ, Mahabeer S, Masters S. Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome. Fertil Steril. 1995;63:58-62.

Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223.

Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev.1997;18:774-800.

Volpi E, Ferrer MD, Rasmussen BB, Urban JR. Relationship between testosterone, body composition and insulin resistance. Diabetes Care. 2005;28:429-432.

Moghetti P, Castello C, Negri C, Tosi FL, Spiazzi GG, Brun EL et al. Insulin infusion amplifies 17α- hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab. 1996;81:881-6.

Diamandis EP, Yu H. New biological functions of prostate specific antigen. J Clin Endocrinol Metab. 1995;80:1515-7.

Goh VHH. Breast tissues in transsexual women: a nonprostatic source of androgen up-regulated production of prostate-specific androgen. J Clin Endocrinol Metab. 1999;84:3313-5.

Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997;43:415-421.

Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren LJ, Yu H et al. Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentration are significantly increased after testosterone administration in female-to-male transsexuals. Clin Chem. 2000; 46:859-862.

Negri C, Tosi F, Dorizzi R, Fortunato A, Spiazzi GG, Muggeo M et al. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab. 2000;85(1):81-84.

Aggarwal RR, Ryan CJ, Chan JM. Chan Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Urol Oncol. 2013;31:522-530.

Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 2009;8:88-96.

Sahra IB, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27:3576-86.

The Rotterdam ESHRE/ASRM—sponsored PCOS Consensus Workshop Group 2004 Revised 2003. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertile Steril. 2004;81:19.

Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995;15:821-6.

Singh B, Panda S, Nanda R, Pati S, Mangaraj M, Sahu PK, et al. Effect of metformin on hormonal and biochemical profile in PCOS before and after therapy. Indian J Clin Biochem. 2010;25(4):367-370.

Richardson MR. Current perspectives in polycystic ovary Syndrome. Am Fam Physician. 2003;68:697-704.

Melegos D, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis EP. Prostate specific antigen in female serum: a potential new marker of androgen excess. J Clin Endocrinol Metab. 1997;82:777-780.

Gullu S, Emral R, Asik M, Cesur M, Tonyukuk V. Diagnostic value of prostatic specific antigen in hirsute women. J Endocrinol Invest. 2003;26:1198-1202.

Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83(8):2694-8.

Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M et al. Metformin effects on clinical features, endocrine and metabolic profiles and insulin sensitivity on polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open–long term clinical evaluation. J ClinEndocrinol Metab. 2000;85(1):139-46.

Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986; 62:904-10.

Eisenhardt S, Schwarzmann N, Henschel V, Germeyer A, Von Wolff M, Hamann A, et al. Early effects of Metformin in women with Polycystic Ovary Syndrome: a prospective Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2006; 91(3):946-52.

Wright JL, Stanford JL Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control. 2009; 20:1617-22.

Ahmed Y E, Ali I H, Ahamed M E, metformin and sulfonylureas effect on the blood level of prostate specific antigen Asian J Pharm Clin Res. 2015;8(2):247-250.

Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Wyler SF et al. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau). World J Urol. 2015; 33(8):1189-96.

Han JH, Lee YT, Kwak KW, Ahn SH, Chang IH, Myung SC, et al. Relationship between insulin resistance, obesity and serum prostate-specific antigen levels in healthy men. Asian J Androl. 2010;12:400-4.